- AstraZeneca and Merck said their castration-resistant prostate cancer drug had met its primary endpoint in clinical trials.

The trial of Lynparza had shown showed a statistically-significant and clinically-meaningful improvement in the primary endpoint of radiographic progression-free survival versus enzalutamide or abiraterone in men with metastatic castration-resistant prostate cancer.

The safety and tolerability profile of Lynparza was generally consistent with previous trials, the company said.

'This trial is the only positive Phase III trial of any PARP inhibitor in metastatic castration-resistant prostate cancer, where the need for new, effective therapies is high,' said JoseĢ Baselga, Executive Vice President, Oncology R&D.

'The PROfound trial also demonstrates the potential value of genomic testing in this at-risk patient population. We look forward to discussing these results with global health authorities soon.'

Story provided by